or Try an Advanced Search...

    Holdings

    Symbol Grade Price % Change Allocation
    NVO B 2.52 3.22
    AZN C 0.70 1.35

    Represented by ETF Holdings

    Keywords: Inflammation Acid Anemia Angina Anti Diabetic Drugs Antibodies Asthma Autoimmune And Inflammatory Disease Biopharmaceutical Bipolar Disorder Breast Cancer Cancer Cholesterol Chronic Condition Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Coronavirus Depressive Disorder Diabetes Diabetes Care
    Industries: Biotechnology Drug Manufacturers - Major

    Recent News for T. Rowe Price Exchange-Traded Funds, Inc. T. Rowe Price International Equity ETF & its Holdings

    Date Stock Title
    Jul 5 NVO Study links GLP-1 drugs, metformin to lower risk of certain cancers
    Jul 5 AZN AstraZeneca & Aptamer partner to bolster targeted siRNA therapies
    Jul 5 NVO Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
    Jul 5 NVO Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code
    Jul 5 AZN AstraZeneca’s Tagrisso plus chemotherapy wins EU approval for NSCLC
    Jul 5 AZN AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
    Jul 5 AZN Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
    Jul 5 NVO Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector
    Jul 5 AZN Investors in AstraZeneca (LON:AZN) have seen strong returns of 115% over the past five years
    Jul 5 AZN What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
    Jul 5 NVO Is It Too Late to Buy Novo Nordisk Stock?
    Jul 5 NVO Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
    Jul 4 NVO Novo Nordisk: Buy On Dips
    Jul 4 NVO NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
    Jul 3 NVO S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
    Jul 3 NVO Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
    Jul 3 NVO Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
    Jul 3 NVO Weight-loss drugs linked to rare vision loss: Harvard study
    Jul 3 NVO Update: Ozempic, Wegovy Linked to Risk of Blinding Eye Condition, Study Shows
    Jul 3 NVO Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study
    The fund normally invests at least 80% of its net assets (including any borrowings for investment purposes) in equity securities. The fund normally invests at least 65% of its net assets (including any borrowings for investment purposes) in non-U.S. stocks. The fund will primarily invest in developed markets.
    Qualified Institutional Buyer
    Back to the Main TOUS Page...